Influenza Diagnostics Market Size, Growth, Demand, Opportunities & Forecast To 2030

The global Influenza Diagnostics market gathered revenue around USD 1.9 Billion in 2020 and market is set to grow USD 3.7 Billion by the end of 2027 and is estimated to expand at a modest CAGR of 9.0% during the prediction period 2021 to 2027.

Request Free Sample of This Report@ https://www.novaoneadvisor.com/report/sample/5775

The market Influenza, commonly known as ‘the flu’, is an infectious disease caused by an influenza virus. Various traditional and molecular diagnostic technologies are used to identify and diagnose influenza. Nowadays, advanced technologies provide highly effective and accurate diagnosis of the influenza.

For instance, reverse transcription-polymerase chain reaction (RT-PCR), or real time, molecular test provides detection of influenza genetic material. Moreover, continued advancements in rapid influenza diagnostic testing (RIDT) have made this method an effective one for diagnosis because of its fast results and ease of specimen collection.

Factors such as increasing prevalence of influenza, growing awareness for early detection using specific diagnostic tests, development of CLIA-waived POC molecular influenza tests, and shifting focus from centralized laboratories to decentralized point-of-care testing are expected to propel the growth of the global market over the coming years.

Report Coverage

Opportunity analysis:

The Human Genome Project and advances in molecular and biomedical technologies have generated a vast amount of data, which have resulted in the development of a multitude of assays and technologies useful for the diagnosis and management of influenza infections. These new technologies, based on genomic techniques (such as PCR-based) and proteomics (such as microarray-based detection), help discover new influenza viruses. They also enable better surveillance and rapid diagnosis of infectious diseases which serves as an opportunity for the market.

Regional Insights

North America is considered to be the key region and accounted for the major revenue share of 32.9% in 2021. The region is expected to continue its dominant position over the forecast period. This growth can be attributed to the increasing government surveillance along with the presence of key players.

By August 2020, U.S. FDA approved 13 rapid influenza diagnostic tests (antigen detection only and excluding the test kits) and 11 multiplex assay for detecting influenza viruses and COVID-19. Similarly, the U.S. healthcare authority released COVID-19 and flu virus testing guidance for Clinicians. Major manufacturers of these players include Becton Dickinson & Co.; Quidel Corp.; and Roche Molecular Systems, Inc.

Ask here for more customization study@ https://www.novaoneadvisor.com/report/customization/5775

Some of the prominent players in the Influenza Diagnostics Market include: Danaher Corporation, Siemens Healthineers, Thermo Fisher Scientific, Inc., F. Hoffmann-LA Roche AG, Abbott Laboratories, Inc., Hologic, Inc., bioMérieux SA, Quidel Corporation, Becton, Dickinson and Company, Meridian Bioscience, GenMark Diagnostics, Inc., Luminex Corporation, Tecan Trading AG, DiaSorin SA, altona Diagnostics GmbH, SEKISUI Diagnostics, SA Scientific Ltd., Coris BioConcept SPRL, ELITech Group, Mast Group Ltd., Genome Diagnostics, Pvt. Ltd.,

Unravelling the Critical Segments

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects including product type, application/end-user, and region. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for period 2017 to 2027 and covers subsequent region in its scope:

By Product

• Test Kit and Reagents
• Instruments
• Other Prodcuts

By Test Type

• Molecular Diagnostic Tests
  • Polymerase Chain Reaction
  • Isothermal Nucleic Acid Amplification Tests
• Transcription-Mediated Amplification-Based Assay
• Loop-Mediated Isothermal Amplification-Based Assay
• Nucleic Acid Sequence-Based Amplification Tests
• Other Isothermal Nucleic Acid Amplification Tests
  • Other Molecular Tests
• Traditional Diagnostic Tests
  • Rapid Influenza Diagnostic Tests
  • Viral Culture Tests
  • Direct Fluorescent Antibody Test
  • Serological Tests

By End User

• Diagnostic Laboratories
• Hospitals and Clinics
• Other End users

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the global Influenza Diagnostics industry analysis from 2022 to 2030 to identify the prevailing Influenza Diagnostics industry opportunity.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter’s five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the global Influenza Diagnostics industry segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global Influenza Diagnostics industry trends, key players, market segments, application areas, and market growth strategies.

Full Report is Ready | For Purchase Inquiry@ https://www.novaoneadvisor.com/report/checkout/5775

You can place an order or ask any questions, please feel free to sales@novaoneadvisor.com| +1 9197 992 333

Blog: https://www.novaoneadvisor.com/

Blog: https://www.visionresearchreports.com/

Blog: https://qyresearchmedical.com/